Takeda (TSE:4502) Stock Climbs As Q2 Earnings Signal Profit Repair

Takeda Pharmaceutical just reported Q2 2027 earnings that show a business pulling out of a painful earnings hole while the share price has quietly been grinding higher. The stock closed at ¥6,651 on 30 October, capping a 30 day move of about 16%. Yet the headline story is about repair, not euphoria.

The real swing factor is profit. Basic earnings per share for the quarter landed at ¥120.71 and quarterly net income reached ¥192.43b, a stark contrast with the large one off loss that still hangs over trailing 12 month figures. Short term optimism now meets a longer memory of balance sheet strain, and that clash of emotion and data will set the tone from here.

Like the earnings recovery story at Takeda Pharmaceutical but wary of balance sheet scars from past losses lingering in the background? Filter for companies that combine earnings power with robust finances using the list of solid balance sheet and fundamentals stocks (20 results)

Q2 2027 Earnings Summary

• Revenue (Q2 2027 vs Q2 2026): ¥1,187,097m vs. ¥1,112,796m (up about 6.7%)
• Net Income (Excl. Extra Items, Q2 2027 vs Q2 2026): ¥192,429m vs. a loss of ¥11,802m (swing back to profit with a very large improvement)
• Basic EPS (Q2 2027 vs Q2 2026): ¥120.71 vs. a loss of ¥7.48 per share (return to positive earnings per share with a very large move higher)
• Late-Stage R&D Pipeline (TTM Q2 2027 vs TTM Q2 2026): 20 products in Phase III vs. 19, and 4 products in pre-registration vs. 7 (slightly larger Phase III pipeline with fewer assets at the pre-registration step)

Tired of scrolling through walls of earnings figures and balance sheet tables to piece together what is really going on at Takeda Pharmaceutical? See the full picture of the business, with a clear visual view of its balance sheet strength and overall financial setup, in the company report for Takeda Pharmaceutical.

Takeda growth story meets real-world milestones

The bullish script hangs on Takeda Pharmaceutical turning VYVANSE and other mature headwinds into a launch led mix powered by orexin, TYK2 and oncology assets.

"Analysts expect Takeda Pharmaceutical to move from the current mix of mature portfolio headwinds and modest core revenue trends toward growth led by new launches such as ORZEYFUL, MIMRYLO and zasocitinib, supported by a broader late stage pipeline and enterprise transformation savings."

H1 FY2026 shows this transition beginning rather than completed. New products are only about 4% of sales yet grew 17.3% at constant currency. Core in line brands were broadly flat. Transformation is tangible, with about ¥30b procurement savings booked toward a ¥100b target and management reiterating guidance after a large swing back to quarterly profit.

Takeda risk narrative tests launch and erosion fears

Bears worry that competitive pressure could overwhelm fresh products if launches misfire or are too small relative to erosion in ENTYVIO and VYVANSE.

"Accelerating generic and biosimilar competition, including advancing vedolizumab biosimilars for ENTYVIO alongside existing pressures on VYVANSE, could weigh more heavily on Takeda Pharmaceutical revenue than current expectations and put sustained pressure on net margins if new products are not large enough to compensate."

Core revenue in H1 FY2026 fell 1% at constant currency, which shows those headwinds are real. At the same time, quarterly net income of ¥192.43b and EPS of ¥120.71 confirm margins are no longer in the deep loss territory of prior periods. ENTYVIO data from VERDICT and a thicker oncology pipeline provide some buffer, although generic drag has not yet clearly stabilised.

The price and this Narrative do not agree. → Uncover what this Narrative says Takeda Pharmaceutical is actually worth.

Hunt For Quiet Fundamental Shifts

Takeda Pharmaceutical just showed how fast a quarterly story can change once profit and sentiment reconnect. The real opportunity is spotting companies that could be undervalued before that kind of reset happens.

• Company 1 - 24% below our estimate - sell form and data platforms firms adopt when legacy reporting breaks under growing transaction volumes.
• Company 2 - 42% below our estimate - supply low code workflow tools that teams switch to when email and spreadsheets stop scaling.
• Company 3 - 27% below our estimate - provide industrial grinding, ceramic and equipment solutions that buyers rely on to tighten production yields.

Those are three of them. See the full list of 15 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com